Global Multiplex Assays

Multiplex Assays Comprehensive Study by Type (Nucleic Acid-Based, Protein-Based, Cell-Based), Application (Companion Diagnostics, Research & Development (Drug Development and Biomarker Discovery & Validation), Clinical Diagnostics), Technology (Multiplex PCR, Multiplex Protein Microarray, Flow Cytometry, Fluorescence Detection, Luminescence), Product (Reagents & Consumables, Accessories & Instruments, Software & Services), End-Use (Hospitals, Clinical Laboratories, Research Institutes, Pharmaceuticals & Biotechnological Companies) Players and Region - Global Market Outlook to 2030

Multiplex Assays Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Multiplex Assays
Multiplex assays enable fast and efficient profiling of multiple proteins in a single well using the multianalyte profiling technology. Numerous antibody-based assay platforms have been developed as alternatives to ELISA for the simultaneous measurement of multiple proteins in a single sample. The most common and well-established format for such multiplex assays makes use of flow-based technology and ligand e.g., antibody coated beads. Most importantly, are able to achieve a more comprehensive study of protein signaling in precious samples when multiplexing. For recognition of the immunoassay sandwich compound, the multiplex assays tools use either light-emitting diodes (LEDs) for excitation of each fluorescent bead combined with a CCD camera for bead and analyse detection, or a flow-based detection system using a red and green laser.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Multiplex Assays market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Luminex Corporation (United States), Thermo Fisher Scientific (United States), Illumina (United States), Bio-Rad Laboratories (United States), Qiagen (Germany), Abcam (United Kingdom), Becton Dickinson and Company (United States), Merck (United States), Agilent Technologies (United States), Meso Scale Diagnostics (United States), Randox Laboratories (United Kingdom), Quanterix (United States) and Bio-Techne (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Seegene Inc (South Korea), Olink (Sweden) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Multiplex Assays market by Type (Nucleic Acid-Based, Protein-Based and Cell-Based), Application (Companion Diagnostics, Research & Development [Drug Development and Biomarker Discovery & Validation] and Clinical Diagnostics) and Region.



On the basis of geography, the market of Multiplex Assays has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Technology, the sub-segment i.e. Multiplex PCR will boost the Multiplex Assays market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Product, the sub-segment i.e. Reagents & Consumables will boost the Multiplex Assays market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-Use, the sub-segment i.e. Hospitals will boost the Multiplex Assays market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Incidence of Cancer and Increasing Adoption of Targeted Therapy

Market Growth Drivers:
Rising Use of Multiplex Assays in Companion Diagnostics and Increasing Adoption due to Advantages over Traditional Assays

Challenges:
High Equipment Costs

Restraints:
Stringent Regulations and Standards

Opportunities:
Increasing Validation of Biomarkers in Molecular and Protein Diagnostics and Improvement in Healthcare Services and Infrastructure in Developing Economies

Market Leaders and their expansionary development strategies
In July 2021, DiaSorin S.p.A. acquired the leading company of multiplex assays, Luminex Corporation, for a price of USD 37.00 per share, that corresponds to a total equity value of approximately USD 1.8 billion.
In June 2023, BioPharma Services, Inc., a Novartis subsidiary and a leading provider of innovative biomarker solutions for drug development, announced the launch of its new multiplex digital PCR assays for comprehensive quantification of multiple chimeric antigen receptor (CAR) T cells, a type of cancer immunotherapy that involves genetically modifying T cells to recognize and destroy certain cancers.


Key Target Audience
Multiplex Assay Providers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Healthcare Industry and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Nucleic Acid-Based
  • Protein-Based
  • Cell-Based
By Application
  • Companion Diagnostics
  • Research & Development [Drug Development and Biomarker Discovery & Validation]
  • Clinical Diagnostics
By Technology
  • Multiplex PCR
  • Multiplex Protein Microarray
  • Flow Cytometry
  • Fluorescence Detection
  • Luminescence

By Product
  • Reagents & Consumables
  • Accessories & Instruments
  • Software & Services

By End-Use
  • Hospitals
  • Clinical Laboratories
  • Research Institutes
  • Pharmaceuticals & Biotechnological Companies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Use of Multiplex Assays in Companion Diagnostics
      • 3.2.2. Increasing Adoption due to Advantages over Traditional Assays
    • 3.3. Market Challenges
      • 3.3.1. High Equipment Costs
    • 3.4. Market Trends
      • 3.4.1. Increasing Incidence of Cancer and Increasing Adoption of Targeted Therapy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Multiplex Assays, by Type, Application, Technology, Product, End-Use and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Multiplex Assays (Value)
      • 5.2.1. Global Multiplex Assays by: Type (Value)
        • 5.2.1.1. Nucleic Acid-Based
        • 5.2.1.2. Protein-Based
        • 5.2.1.3. Cell-Based
      • 5.2.2. Global Multiplex Assays by: Application (Value)
        • 5.2.2.1. Companion Diagnostics
        • 5.2.2.2. Research & Development [Drug Development and Biomarker Discovery & Validation]
        • 5.2.2.3. Clinical Diagnostics
      • 5.2.3. Global Multiplex Assays by: Technology (Value)
        • 5.2.3.1. Multiplex PCR
        • 5.2.3.2. Multiplex Protein Microarray
        • 5.2.3.3. Flow Cytometry
        • 5.2.3.4. Fluorescence Detection
        • 5.2.3.5. Luminescence
      • 5.2.4. Global Multiplex Assays by: Product (Value)
        • 5.2.4.1. Reagents & Consumables
        • 5.2.4.2. Accessories & Instruments
        • 5.2.4.3. Software & Services
      • 5.2.5. Global Multiplex Assays by: End-Use (Value)
        • 5.2.5.1. Hospitals
        • 5.2.5.2. Clinical Laboratories
        • 5.2.5.3. Research Institutes
        • 5.2.5.4. Pharmaceuticals & Biotechnological Companies
      • 5.2.6. Global Multiplex Assays Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Multiplex Assays (Volume)
      • 5.3.1. Global Multiplex Assays by: Type (Volume)
        • 5.3.1.1. Nucleic Acid-Based
        • 5.3.1.2. Protein-Based
        • 5.3.1.3. Cell-Based
      • 5.3.2. Global Multiplex Assays by: Application (Volume)
        • 5.3.2.1. Companion Diagnostics
        • 5.3.2.2. Research & Development [Drug Development and Biomarker Discovery & Validation]
        • 5.3.2.3. Clinical Diagnostics
      • 5.3.3. Global Multiplex Assays by: Technology (Volume)
        • 5.3.3.1. Multiplex PCR
        • 5.3.3.2. Multiplex Protein Microarray
        • 5.3.3.3. Flow Cytometry
        • 5.3.3.4. Fluorescence Detection
        • 5.3.3.5. Luminescence
      • 5.3.4. Global Multiplex Assays by: Product (Volume)
        • 5.3.4.1. Reagents & Consumables
        • 5.3.4.2. Accessories & Instruments
        • 5.3.4.3. Software & Services
      • 5.3.5. Global Multiplex Assays by: End-Use (Volume)
        • 5.3.5.1. Hospitals
        • 5.3.5.2. Clinical Laboratories
        • 5.3.5.3. Research Institutes
        • 5.3.5.4. Pharmaceuticals & Biotechnological Companies
      • 5.3.6. Global Multiplex Assays Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Multiplex Assays (Price)
      • 5.4.1. Global Multiplex Assays by: Type (Price)
  • 6. Multiplex Assays: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Luminex Corporation (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Thermo Fisher Scientific (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Illumina (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bio-Rad Laboratories (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Qiagen (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Abcam (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Becton Dickinson and Company (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Agilent Technologies (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Meso Scale Diagnostics (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Randox Laboratories (United Kingdom)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Quanterix (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Bio-Techne (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Multiplex Assays Sale, by Type, Application, Technology, Product, End-Use and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Multiplex Assays (Value)
      • 7.2.1. Global Multiplex Assays by: Type (Value)
        • 7.2.1.1. Nucleic Acid-Based
        • 7.2.1.2. Protein-Based
        • 7.2.1.3. Cell-Based
      • 7.2.2. Global Multiplex Assays by: Application (Value)
        • 7.2.2.1. Companion Diagnostics
        • 7.2.2.2. Research & Development [Drug Development and Biomarker Discovery & Validation]
        • 7.2.2.3. Clinical Diagnostics
      • 7.2.3. Global Multiplex Assays by: Technology (Value)
        • 7.2.3.1. Multiplex PCR
        • 7.2.3.2. Multiplex Protein Microarray
        • 7.2.3.3. Flow Cytometry
        • 7.2.3.4. Fluorescence Detection
        • 7.2.3.5. Luminescence
      • 7.2.4. Global Multiplex Assays by: Product (Value)
        • 7.2.4.1. Reagents & Consumables
        • 7.2.4.2. Accessories & Instruments
        • 7.2.4.3. Software & Services
      • 7.2.5. Global Multiplex Assays by: End-Use (Value)
        • 7.2.5.1. Hospitals
        • 7.2.5.2. Clinical Laboratories
        • 7.2.5.3. Research Institutes
        • 7.2.5.4. Pharmaceuticals & Biotechnological Companies
      • 7.2.6. Global Multiplex Assays Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Multiplex Assays (Volume)
      • 7.3.1. Global Multiplex Assays by: Type (Volume)
        • 7.3.1.1. Nucleic Acid-Based
        • 7.3.1.2. Protein-Based
        • 7.3.1.3. Cell-Based
      • 7.3.2. Global Multiplex Assays by: Application (Volume)
        • 7.3.2.1. Companion Diagnostics
        • 7.3.2.2. Research & Development [Drug Development and Biomarker Discovery & Validation]
        • 7.3.2.3. Clinical Diagnostics
      • 7.3.3. Global Multiplex Assays by: Technology (Volume)
        • 7.3.3.1. Multiplex PCR
        • 7.3.3.2. Multiplex Protein Microarray
        • 7.3.3.3. Flow Cytometry
        • 7.3.3.4. Fluorescence Detection
        • 7.3.3.5. Luminescence
      • 7.3.4. Global Multiplex Assays by: Product (Volume)
        • 7.3.4.1. Reagents & Consumables
        • 7.3.4.2. Accessories & Instruments
        • 7.3.4.3. Software & Services
      • 7.3.5. Global Multiplex Assays by: End-Use (Volume)
        • 7.3.5.1. Hospitals
        • 7.3.5.2. Clinical Laboratories
        • 7.3.5.3. Research Institutes
        • 7.3.5.4. Pharmaceuticals & Biotechnological Companies
      • 7.3.6. Global Multiplex Assays Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Multiplex Assays (Price)
      • 7.4.1. Global Multiplex Assays by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Multiplex Assays: by Type(USD Million)
  • Table 2. Multiplex Assays Nucleic Acid-Based , by Region USD Million (2018-2023)
  • Table 3. Multiplex Assays Protein-Based , by Region USD Million (2018-2023)
  • Table 4. Multiplex Assays Cell-Based , by Region USD Million (2018-2023)
  • Table 5. Multiplex Assays: by Application(USD Million)
  • Table 6. Multiplex Assays Companion Diagnostics , by Region USD Million (2018-2023)
  • Table 7. Multiplex Assays Research & Development [Drug Development and Biomarker Discovery & Validation] , by Region USD Million (2018-2023)
  • Table 8. Multiplex Assays Clinical Diagnostics , by Region USD Million (2018-2023)
  • Table 9. Multiplex Assays: by Technology(USD Million)
  • Table 10. Multiplex Assays Multiplex PCR , by Region USD Million (2018-2023)
  • Table 11. Multiplex Assays Multiplex Protein Microarray , by Region USD Million (2018-2023)
  • Table 12. Multiplex Assays Flow Cytometry , by Region USD Million (2018-2023)
  • Table 13. Multiplex Assays Fluorescence Detection , by Region USD Million (2018-2023)
  • Table 14. Multiplex Assays Luminescence , by Region USD Million (2018-2023)
  • Table 15. Multiplex Assays: by Product(USD Million)
  • Table 16. Multiplex Assays Reagents & Consumables , by Region USD Million (2018-2023)
  • Table 17. Multiplex Assays Accessories & Instruments , by Region USD Million (2018-2023)
  • Table 18. Multiplex Assays Software & Services , by Region USD Million (2018-2023)
  • Table 19. Multiplex Assays: by End-Use(USD Million)
  • Table 20. Multiplex Assays Hospitals , by Region USD Million (2018-2023)
  • Table 21. Multiplex Assays Clinical Laboratories , by Region USD Million (2018-2023)
  • Table 22. Multiplex Assays Research Institutes , by Region USD Million (2018-2023)
  • Table 23. Multiplex Assays Pharmaceuticals & Biotechnological Companies , by Region USD Million (2018-2023)
  • Table 24. South America Multiplex Assays, by Country USD Million (2018-2023)
  • Table 25. South America Multiplex Assays, by Type USD Million (2018-2023)
  • Table 26. South America Multiplex Assays, by Application USD Million (2018-2023)
  • Table 27. South America Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 28. South America Multiplex Assays, by Product USD Million (2018-2023)
  • Table 29. South America Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 30. Brazil Multiplex Assays, by Type USD Million (2018-2023)
  • Table 31. Brazil Multiplex Assays, by Application USD Million (2018-2023)
  • Table 32. Brazil Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 33. Brazil Multiplex Assays, by Product USD Million (2018-2023)
  • Table 34. Brazil Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 35. Argentina Multiplex Assays, by Type USD Million (2018-2023)
  • Table 36. Argentina Multiplex Assays, by Application USD Million (2018-2023)
  • Table 37. Argentina Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 38. Argentina Multiplex Assays, by Product USD Million (2018-2023)
  • Table 39. Argentina Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 40. Rest of South America Multiplex Assays, by Type USD Million (2018-2023)
  • Table 41. Rest of South America Multiplex Assays, by Application USD Million (2018-2023)
  • Table 42. Rest of South America Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 43. Rest of South America Multiplex Assays, by Product USD Million (2018-2023)
  • Table 44. Rest of South America Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 45. Asia Pacific Multiplex Assays, by Country USD Million (2018-2023)
  • Table 46. Asia Pacific Multiplex Assays, by Type USD Million (2018-2023)
  • Table 47. Asia Pacific Multiplex Assays, by Application USD Million (2018-2023)
  • Table 48. Asia Pacific Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 49. Asia Pacific Multiplex Assays, by Product USD Million (2018-2023)
  • Table 50. Asia Pacific Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 51. China Multiplex Assays, by Type USD Million (2018-2023)
  • Table 52. China Multiplex Assays, by Application USD Million (2018-2023)
  • Table 53. China Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 54. China Multiplex Assays, by Product USD Million (2018-2023)
  • Table 55. China Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 56. Japan Multiplex Assays, by Type USD Million (2018-2023)
  • Table 57. Japan Multiplex Assays, by Application USD Million (2018-2023)
  • Table 58. Japan Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 59. Japan Multiplex Assays, by Product USD Million (2018-2023)
  • Table 60. Japan Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 61. India Multiplex Assays, by Type USD Million (2018-2023)
  • Table 62. India Multiplex Assays, by Application USD Million (2018-2023)
  • Table 63. India Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 64. India Multiplex Assays, by Product USD Million (2018-2023)
  • Table 65. India Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 66. South Korea Multiplex Assays, by Type USD Million (2018-2023)
  • Table 67. South Korea Multiplex Assays, by Application USD Million (2018-2023)
  • Table 68. South Korea Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 69. South Korea Multiplex Assays, by Product USD Million (2018-2023)
  • Table 70. South Korea Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 71. Taiwan Multiplex Assays, by Type USD Million (2018-2023)
  • Table 72. Taiwan Multiplex Assays, by Application USD Million (2018-2023)
  • Table 73. Taiwan Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 74. Taiwan Multiplex Assays, by Product USD Million (2018-2023)
  • Table 75. Taiwan Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 76. Australia Multiplex Assays, by Type USD Million (2018-2023)
  • Table 77. Australia Multiplex Assays, by Application USD Million (2018-2023)
  • Table 78. Australia Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 79. Australia Multiplex Assays, by Product USD Million (2018-2023)
  • Table 80. Australia Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 81. Rest of Asia-Pacific Multiplex Assays, by Type USD Million (2018-2023)
  • Table 82. Rest of Asia-Pacific Multiplex Assays, by Application USD Million (2018-2023)
  • Table 83. Rest of Asia-Pacific Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 84. Rest of Asia-Pacific Multiplex Assays, by Product USD Million (2018-2023)
  • Table 85. Rest of Asia-Pacific Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 86. Europe Multiplex Assays, by Country USD Million (2018-2023)
  • Table 87. Europe Multiplex Assays, by Type USD Million (2018-2023)
  • Table 88. Europe Multiplex Assays, by Application USD Million (2018-2023)
  • Table 89. Europe Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 90. Europe Multiplex Assays, by Product USD Million (2018-2023)
  • Table 91. Europe Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 92. Germany Multiplex Assays, by Type USD Million (2018-2023)
  • Table 93. Germany Multiplex Assays, by Application USD Million (2018-2023)
  • Table 94. Germany Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 95. Germany Multiplex Assays, by Product USD Million (2018-2023)
  • Table 96. Germany Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 97. France Multiplex Assays, by Type USD Million (2018-2023)
  • Table 98. France Multiplex Assays, by Application USD Million (2018-2023)
  • Table 99. France Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 100. France Multiplex Assays, by Product USD Million (2018-2023)
  • Table 101. France Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 102. Italy Multiplex Assays, by Type USD Million (2018-2023)
  • Table 103. Italy Multiplex Assays, by Application USD Million (2018-2023)
  • Table 104. Italy Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 105. Italy Multiplex Assays, by Product USD Million (2018-2023)
  • Table 106. Italy Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 107. United Kingdom Multiplex Assays, by Type USD Million (2018-2023)
  • Table 108. United Kingdom Multiplex Assays, by Application USD Million (2018-2023)
  • Table 109. United Kingdom Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 110. United Kingdom Multiplex Assays, by Product USD Million (2018-2023)
  • Table 111. United Kingdom Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 112. Netherlands Multiplex Assays, by Type USD Million (2018-2023)
  • Table 113. Netherlands Multiplex Assays, by Application USD Million (2018-2023)
  • Table 114. Netherlands Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 115. Netherlands Multiplex Assays, by Product USD Million (2018-2023)
  • Table 116. Netherlands Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 117. Rest of Europe Multiplex Assays, by Type USD Million (2018-2023)
  • Table 118. Rest of Europe Multiplex Assays, by Application USD Million (2018-2023)
  • Table 119. Rest of Europe Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 120. Rest of Europe Multiplex Assays, by Product USD Million (2018-2023)
  • Table 121. Rest of Europe Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 122. MEA Multiplex Assays, by Country USD Million (2018-2023)
  • Table 123. MEA Multiplex Assays, by Type USD Million (2018-2023)
  • Table 124. MEA Multiplex Assays, by Application USD Million (2018-2023)
  • Table 125. MEA Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 126. MEA Multiplex Assays, by Product USD Million (2018-2023)
  • Table 127. MEA Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 128. Middle East Multiplex Assays, by Type USD Million (2018-2023)
  • Table 129. Middle East Multiplex Assays, by Application USD Million (2018-2023)
  • Table 130. Middle East Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 131. Middle East Multiplex Assays, by Product USD Million (2018-2023)
  • Table 132. Middle East Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 133. Africa Multiplex Assays, by Type USD Million (2018-2023)
  • Table 134. Africa Multiplex Assays, by Application USD Million (2018-2023)
  • Table 135. Africa Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 136. Africa Multiplex Assays, by Product USD Million (2018-2023)
  • Table 137. Africa Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 138. North America Multiplex Assays, by Country USD Million (2018-2023)
  • Table 139. North America Multiplex Assays, by Type USD Million (2018-2023)
  • Table 140. North America Multiplex Assays, by Application USD Million (2018-2023)
  • Table 141. North America Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 142. North America Multiplex Assays, by Product USD Million (2018-2023)
  • Table 143. North America Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 144. United States Multiplex Assays, by Type USD Million (2018-2023)
  • Table 145. United States Multiplex Assays, by Application USD Million (2018-2023)
  • Table 146. United States Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 147. United States Multiplex Assays, by Product USD Million (2018-2023)
  • Table 148. United States Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 149. Canada Multiplex Assays, by Type USD Million (2018-2023)
  • Table 150. Canada Multiplex Assays, by Application USD Million (2018-2023)
  • Table 151. Canada Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 152. Canada Multiplex Assays, by Product USD Million (2018-2023)
  • Table 153. Canada Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 154. Mexico Multiplex Assays, by Type USD Million (2018-2023)
  • Table 155. Mexico Multiplex Assays, by Application USD Million (2018-2023)
  • Table 156. Mexico Multiplex Assays, by Technology USD Million (2018-2023)
  • Table 157. Mexico Multiplex Assays, by Product USD Million (2018-2023)
  • Table 158. Mexico Multiplex Assays, by End-Use USD Million (2018-2023)
  • Table 159. Multiplex Assays Sales: by Type(K Units)
  • Table 160. Multiplex Assays Sales Nucleic Acid-Based , by Region K Units (2018-2023)
  • Table 161. Multiplex Assays Sales Protein-Based , by Region K Units (2018-2023)
  • Table 162. Multiplex Assays Sales Cell-Based , by Region K Units (2018-2023)
  • Table 163. Multiplex Assays Sales: by Application(K Units)
  • Table 164. Multiplex Assays Sales Companion Diagnostics , by Region K Units (2018-2023)
  • Table 165. Multiplex Assays Sales Research & Development [Drug Development and Biomarker Discovery & Validation] , by Region K Units (2018-2023)
  • Table 166. Multiplex Assays Sales Clinical Diagnostics , by Region K Units (2018-2023)
  • Table 167. Multiplex Assays Sales: by Technology(K Units)
  • Table 168. Multiplex Assays Sales Multiplex PCR , by Region K Units (2018-2023)
  • Table 169. Multiplex Assays Sales Multiplex Protein Microarray , by Region K Units (2018-2023)
  • Table 170. Multiplex Assays Sales Flow Cytometry , by Region K Units (2018-2023)
  • Table 171. Multiplex Assays Sales Fluorescence Detection , by Region K Units (2018-2023)
  • Table 172. Multiplex Assays Sales Luminescence , by Region K Units (2018-2023)
  • Table 173. Multiplex Assays Sales: by Product(K Units)
  • Table 174. Multiplex Assays Sales Reagents & Consumables , by Region K Units (2018-2023)
  • Table 175. Multiplex Assays Sales Accessories & Instruments , by Region K Units (2018-2023)
  • Table 176. Multiplex Assays Sales Software & Services , by Region K Units (2018-2023)
  • Table 177. Multiplex Assays Sales: by End-Use(K Units)
  • Table 178. Multiplex Assays Sales Hospitals , by Region K Units (2018-2023)
  • Table 179. Multiplex Assays Sales Clinical Laboratories , by Region K Units (2018-2023)
  • Table 180. Multiplex Assays Sales Research Institutes , by Region K Units (2018-2023)
  • Table 181. Multiplex Assays Sales Pharmaceuticals & Biotechnological Companies , by Region K Units (2018-2023)
  • Table 182. South America Multiplex Assays Sales, by Country K Units (2018-2023)
  • Table 183. South America Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 184. South America Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 185. South America Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 186. South America Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 187. South America Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 188. Brazil Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 189. Brazil Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 190. Brazil Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 191. Brazil Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 192. Brazil Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 193. Argentina Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 194. Argentina Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 195. Argentina Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 196. Argentina Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 197. Argentina Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 198. Rest of South America Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 199. Rest of South America Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 200. Rest of South America Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 201. Rest of South America Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 202. Rest of South America Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 203. Asia Pacific Multiplex Assays Sales, by Country K Units (2018-2023)
  • Table 204. Asia Pacific Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 205. Asia Pacific Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 206. Asia Pacific Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 207. Asia Pacific Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 208. Asia Pacific Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 209. China Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 210. China Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 211. China Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 212. China Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 213. China Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 214. Japan Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 215. Japan Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 216. Japan Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 217. Japan Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 218. Japan Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 219. India Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 220. India Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 221. India Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 222. India Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 223. India Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 224. South Korea Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 225. South Korea Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 226. South Korea Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 227. South Korea Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 228. South Korea Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 229. Taiwan Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 230. Taiwan Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 231. Taiwan Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 232. Taiwan Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 233. Taiwan Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 234. Australia Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 235. Australia Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 236. Australia Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 237. Australia Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 238. Australia Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 239. Rest of Asia-Pacific Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 240. Rest of Asia-Pacific Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 241. Rest of Asia-Pacific Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 242. Rest of Asia-Pacific Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 243. Rest of Asia-Pacific Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 244. Europe Multiplex Assays Sales, by Country K Units (2018-2023)
  • Table 245. Europe Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 246. Europe Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 247. Europe Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 248. Europe Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 249. Europe Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 250. Germany Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 251. Germany Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 252. Germany Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 253. Germany Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 254. Germany Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 255. France Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 256. France Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 257. France Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 258. France Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 259. France Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 260. Italy Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 261. Italy Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 262. Italy Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 263. Italy Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 264. Italy Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 265. United Kingdom Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 266. United Kingdom Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 267. United Kingdom Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 268. United Kingdom Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 269. United Kingdom Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 270. Netherlands Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 271. Netherlands Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 272. Netherlands Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 273. Netherlands Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 274. Netherlands Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 275. Rest of Europe Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 276. Rest of Europe Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 277. Rest of Europe Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 278. Rest of Europe Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 279. Rest of Europe Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 280. MEA Multiplex Assays Sales, by Country K Units (2018-2023)
  • Table 281. MEA Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 282. MEA Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 283. MEA Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 284. MEA Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 285. MEA Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 286. Middle East Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 287. Middle East Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 288. Middle East Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 289. Middle East Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 290. Middle East Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 291. Africa Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 292. Africa Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 293. Africa Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 294. Africa Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 295. Africa Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 296. North America Multiplex Assays Sales, by Country K Units (2018-2023)
  • Table 297. North America Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 298. North America Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 299. North America Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 300. North America Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 301. North America Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 302. United States Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 303. United States Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 304. United States Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 305. United States Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 306. United States Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 307. Canada Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 308. Canada Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 309. Canada Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 310. Canada Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 311. Canada Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 312. Mexico Multiplex Assays Sales, by Type K Units (2018-2023)
  • Table 313. Mexico Multiplex Assays Sales, by Application K Units (2018-2023)
  • Table 314. Mexico Multiplex Assays Sales, by Technology K Units (2018-2023)
  • Table 315. Mexico Multiplex Assays Sales, by Product K Units (2018-2023)
  • Table 316. Mexico Multiplex Assays Sales, by End-Use K Units (2018-2023)
  • Table 317. Multiplex Assays: by Type(USD/Units)
  • Table 318. Company Basic Information, Sales Area and Its Competitors
  • Table 319. Company Basic Information, Sales Area and Its Competitors
  • Table 320. Company Basic Information, Sales Area and Its Competitors
  • Table 321. Company Basic Information, Sales Area and Its Competitors
  • Table 322. Company Basic Information, Sales Area and Its Competitors
  • Table 323. Company Basic Information, Sales Area and Its Competitors
  • Table 324. Company Basic Information, Sales Area and Its Competitors
  • Table 325. Company Basic Information, Sales Area and Its Competitors
  • Table 326. Company Basic Information, Sales Area and Its Competitors
  • Table 327. Company Basic Information, Sales Area and Its Competitors
  • Table 328. Company Basic Information, Sales Area and Its Competitors
  • Table 329. Company Basic Information, Sales Area and Its Competitors
  • Table 330. Company Basic Information, Sales Area and Its Competitors
  • Table 331. Multiplex Assays: by Type(USD Million)
  • Table 332. Multiplex Assays Nucleic Acid-Based , by Region USD Million (2025-2030)
  • Table 333. Multiplex Assays Protein-Based , by Region USD Million (2025-2030)
  • Table 334. Multiplex Assays Cell-Based , by Region USD Million (2025-2030)
  • Table 335. Multiplex Assays: by Application(USD Million)
  • Table 336. Multiplex Assays Companion Diagnostics , by Region USD Million (2025-2030)
  • Table 337. Multiplex Assays Research & Development [Drug Development and Biomarker Discovery & Validation] , by Region USD Million (2025-2030)
  • Table 338. Multiplex Assays Clinical Diagnostics , by Region USD Million (2025-2030)
  • Table 339. Multiplex Assays: by Technology(USD Million)
  • Table 340. Multiplex Assays Multiplex PCR , by Region USD Million (2025-2030)
  • Table 341. Multiplex Assays Multiplex Protein Microarray , by Region USD Million (2025-2030)
  • Table 342. Multiplex Assays Flow Cytometry , by Region USD Million (2025-2030)
  • Table 343. Multiplex Assays Fluorescence Detection , by Region USD Million (2025-2030)
  • Table 344. Multiplex Assays Luminescence , by Region USD Million (2025-2030)
  • Table 345. Multiplex Assays: by Product(USD Million)
  • Table 346. Multiplex Assays Reagents & Consumables , by Region USD Million (2025-2030)
  • Table 347. Multiplex Assays Accessories & Instruments , by Region USD Million (2025-2030)
  • Table 348. Multiplex Assays Software & Services , by Region USD Million (2025-2030)
  • Table 349. Multiplex Assays: by End-Use(USD Million)
  • Table 350. Multiplex Assays Hospitals , by Region USD Million (2025-2030)
  • Table 351. Multiplex Assays Clinical Laboratories , by Region USD Million (2025-2030)
  • Table 352. Multiplex Assays Research Institutes , by Region USD Million (2025-2030)
  • Table 353. Multiplex Assays Pharmaceuticals & Biotechnological Companies , by Region USD Million (2025-2030)
  • Table 354. South America Multiplex Assays, by Country USD Million (2025-2030)
  • Table 355. South America Multiplex Assays, by Type USD Million (2025-2030)
  • Table 356. South America Multiplex Assays, by Application USD Million (2025-2030)
  • Table 357. South America Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 358. South America Multiplex Assays, by Product USD Million (2025-2030)
  • Table 359. South America Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 360. Brazil Multiplex Assays, by Type USD Million (2025-2030)
  • Table 361. Brazil Multiplex Assays, by Application USD Million (2025-2030)
  • Table 362. Brazil Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 363. Brazil Multiplex Assays, by Product USD Million (2025-2030)
  • Table 364. Brazil Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 365. Argentina Multiplex Assays, by Type USD Million (2025-2030)
  • Table 366. Argentina Multiplex Assays, by Application USD Million (2025-2030)
  • Table 367. Argentina Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 368. Argentina Multiplex Assays, by Product USD Million (2025-2030)
  • Table 369. Argentina Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 370. Rest of South America Multiplex Assays, by Type USD Million (2025-2030)
  • Table 371. Rest of South America Multiplex Assays, by Application USD Million (2025-2030)
  • Table 372. Rest of South America Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 373. Rest of South America Multiplex Assays, by Product USD Million (2025-2030)
  • Table 374. Rest of South America Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 375. Asia Pacific Multiplex Assays, by Country USD Million (2025-2030)
  • Table 376. Asia Pacific Multiplex Assays, by Type USD Million (2025-2030)
  • Table 377. Asia Pacific Multiplex Assays, by Application USD Million (2025-2030)
  • Table 378. Asia Pacific Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 379. Asia Pacific Multiplex Assays, by Product USD Million (2025-2030)
  • Table 380. Asia Pacific Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 381. China Multiplex Assays, by Type USD Million (2025-2030)
  • Table 382. China Multiplex Assays, by Application USD Million (2025-2030)
  • Table 383. China Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 384. China Multiplex Assays, by Product USD Million (2025-2030)
  • Table 385. China Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 386. Japan Multiplex Assays, by Type USD Million (2025-2030)
  • Table 387. Japan Multiplex Assays, by Application USD Million (2025-2030)
  • Table 388. Japan Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 389. Japan Multiplex Assays, by Product USD Million (2025-2030)
  • Table 390. Japan Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 391. India Multiplex Assays, by Type USD Million (2025-2030)
  • Table 392. India Multiplex Assays, by Application USD Million (2025-2030)
  • Table 393. India Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 394. India Multiplex Assays, by Product USD Million (2025-2030)
  • Table 395. India Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 396. South Korea Multiplex Assays, by Type USD Million (2025-2030)
  • Table 397. South Korea Multiplex Assays, by Application USD Million (2025-2030)
  • Table 398. South Korea Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 399. South Korea Multiplex Assays, by Product USD Million (2025-2030)
  • Table 400. South Korea Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 401. Taiwan Multiplex Assays, by Type USD Million (2025-2030)
  • Table 402. Taiwan Multiplex Assays, by Application USD Million (2025-2030)
  • Table 403. Taiwan Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 404. Taiwan Multiplex Assays, by Product USD Million (2025-2030)
  • Table 405. Taiwan Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 406. Australia Multiplex Assays, by Type USD Million (2025-2030)
  • Table 407. Australia Multiplex Assays, by Application USD Million (2025-2030)
  • Table 408. Australia Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 409. Australia Multiplex Assays, by Product USD Million (2025-2030)
  • Table 410. Australia Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 411. Rest of Asia-Pacific Multiplex Assays, by Type USD Million (2025-2030)
  • Table 412. Rest of Asia-Pacific Multiplex Assays, by Application USD Million (2025-2030)
  • Table 413. Rest of Asia-Pacific Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 414. Rest of Asia-Pacific Multiplex Assays, by Product USD Million (2025-2030)
  • Table 415. Rest of Asia-Pacific Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 416. Europe Multiplex Assays, by Country USD Million (2025-2030)
  • Table 417. Europe Multiplex Assays, by Type USD Million (2025-2030)
  • Table 418. Europe Multiplex Assays, by Application USD Million (2025-2030)
  • Table 419. Europe Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 420. Europe Multiplex Assays, by Product USD Million (2025-2030)
  • Table 421. Europe Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 422. Germany Multiplex Assays, by Type USD Million (2025-2030)
  • Table 423. Germany Multiplex Assays, by Application USD Million (2025-2030)
  • Table 424. Germany Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 425. Germany Multiplex Assays, by Product USD Million (2025-2030)
  • Table 426. Germany Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 427. France Multiplex Assays, by Type USD Million (2025-2030)
  • Table 428. France Multiplex Assays, by Application USD Million (2025-2030)
  • Table 429. France Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 430. France Multiplex Assays, by Product USD Million (2025-2030)
  • Table 431. France Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 432. Italy Multiplex Assays, by Type USD Million (2025-2030)
  • Table 433. Italy Multiplex Assays, by Application USD Million (2025-2030)
  • Table 434. Italy Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 435. Italy Multiplex Assays, by Product USD Million (2025-2030)
  • Table 436. Italy Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 437. United Kingdom Multiplex Assays, by Type USD Million (2025-2030)
  • Table 438. United Kingdom Multiplex Assays, by Application USD Million (2025-2030)
  • Table 439. United Kingdom Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 440. United Kingdom Multiplex Assays, by Product USD Million (2025-2030)
  • Table 441. United Kingdom Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 442. Netherlands Multiplex Assays, by Type USD Million (2025-2030)
  • Table 443. Netherlands Multiplex Assays, by Application USD Million (2025-2030)
  • Table 444. Netherlands Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 445. Netherlands Multiplex Assays, by Product USD Million (2025-2030)
  • Table 446. Netherlands Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 447. Rest of Europe Multiplex Assays, by Type USD Million (2025-2030)
  • Table 448. Rest of Europe Multiplex Assays, by Application USD Million (2025-2030)
  • Table 449. Rest of Europe Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 450. Rest of Europe Multiplex Assays, by Product USD Million (2025-2030)
  • Table 451. Rest of Europe Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 452. MEA Multiplex Assays, by Country USD Million (2025-2030)
  • Table 453. MEA Multiplex Assays, by Type USD Million (2025-2030)
  • Table 454. MEA Multiplex Assays, by Application USD Million (2025-2030)
  • Table 455. MEA Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 456. MEA Multiplex Assays, by Product USD Million (2025-2030)
  • Table 457. MEA Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 458. Middle East Multiplex Assays, by Type USD Million (2025-2030)
  • Table 459. Middle East Multiplex Assays, by Application USD Million (2025-2030)
  • Table 460. Middle East Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 461. Middle East Multiplex Assays, by Product USD Million (2025-2030)
  • Table 462. Middle East Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 463. Africa Multiplex Assays, by Type USD Million (2025-2030)
  • Table 464. Africa Multiplex Assays, by Application USD Million (2025-2030)
  • Table 465. Africa Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 466. Africa Multiplex Assays, by Product USD Million (2025-2030)
  • Table 467. Africa Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 468. North America Multiplex Assays, by Country USD Million (2025-2030)
  • Table 469. North America Multiplex Assays, by Type USD Million (2025-2030)
  • Table 470. North America Multiplex Assays, by Application USD Million (2025-2030)
  • Table 471. North America Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 472. North America Multiplex Assays, by Product USD Million (2025-2030)
  • Table 473. North America Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 474. United States Multiplex Assays, by Type USD Million (2025-2030)
  • Table 475. United States Multiplex Assays, by Application USD Million (2025-2030)
  • Table 476. United States Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 477. United States Multiplex Assays, by Product USD Million (2025-2030)
  • Table 478. United States Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 479. Canada Multiplex Assays, by Type USD Million (2025-2030)
  • Table 480. Canada Multiplex Assays, by Application USD Million (2025-2030)
  • Table 481. Canada Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 482. Canada Multiplex Assays, by Product USD Million (2025-2030)
  • Table 483. Canada Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 484. Mexico Multiplex Assays, by Type USD Million (2025-2030)
  • Table 485. Mexico Multiplex Assays, by Application USD Million (2025-2030)
  • Table 486. Mexico Multiplex Assays, by Technology USD Million (2025-2030)
  • Table 487. Mexico Multiplex Assays, by Product USD Million (2025-2030)
  • Table 488. Mexico Multiplex Assays, by End-Use USD Million (2025-2030)
  • Table 489. Multiplex Assays Sales: by Type(K Units)
  • Table 490. Multiplex Assays Sales Nucleic Acid-Based , by Region K Units (2025-2030)
  • Table 491. Multiplex Assays Sales Protein-Based , by Region K Units (2025-2030)
  • Table 492. Multiplex Assays Sales Cell-Based , by Region K Units (2025-2030)
  • Table 493. Multiplex Assays Sales: by Application(K Units)
  • Table 494. Multiplex Assays Sales Companion Diagnostics , by Region K Units (2025-2030)
  • Table 495. Multiplex Assays Sales Research & Development [Drug Development and Biomarker Discovery & Validation] , by Region K Units (2025-2030)
  • Table 496. Multiplex Assays Sales Clinical Diagnostics , by Region K Units (2025-2030)
  • Table 497. Multiplex Assays Sales: by Technology(K Units)
  • Table 498. Multiplex Assays Sales Multiplex PCR , by Region K Units (2025-2030)
  • Table 499. Multiplex Assays Sales Multiplex Protein Microarray , by Region K Units (2025-2030)
  • Table 500. Multiplex Assays Sales Flow Cytometry , by Region K Units (2025-2030)
  • Table 501. Multiplex Assays Sales Fluorescence Detection , by Region K Units (2025-2030)
  • Table 502. Multiplex Assays Sales Luminescence , by Region K Units (2025-2030)
  • Table 503. Multiplex Assays Sales: by Product(K Units)
  • Table 504. Multiplex Assays Sales Reagents & Consumables , by Region K Units (2025-2030)
  • Table 505. Multiplex Assays Sales Accessories & Instruments , by Region K Units (2025-2030)
  • Table 506. Multiplex Assays Sales Software & Services , by Region K Units (2025-2030)
  • Table 507. Multiplex Assays Sales: by End-Use(K Units)
  • Table 508. Multiplex Assays Sales Hospitals , by Region K Units (2025-2030)
  • Table 509. Multiplex Assays Sales Clinical Laboratories , by Region K Units (2025-2030)
  • Table 510. Multiplex Assays Sales Research Institutes , by Region K Units (2025-2030)
  • Table 511. Multiplex Assays Sales Pharmaceuticals & Biotechnological Companies , by Region K Units (2025-2030)
  • Table 512. South America Multiplex Assays Sales, by Country K Units (2025-2030)
  • Table 513. South America Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 514. South America Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 515. South America Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 516. South America Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 517. South America Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 518. Brazil Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 519. Brazil Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 520. Brazil Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 521. Brazil Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 522. Brazil Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 523. Argentina Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 524. Argentina Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 525. Argentina Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 526. Argentina Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 527. Argentina Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 528. Rest of South America Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 529. Rest of South America Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 530. Rest of South America Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 531. Rest of South America Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 532. Rest of South America Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 533. Asia Pacific Multiplex Assays Sales, by Country K Units (2025-2030)
  • Table 534. Asia Pacific Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 535. Asia Pacific Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 536. Asia Pacific Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 537. Asia Pacific Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 538. Asia Pacific Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 539. China Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 540. China Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 541. China Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 542. China Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 543. China Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 544. Japan Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 545. Japan Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 546. Japan Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 547. Japan Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 548. Japan Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 549. India Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 550. India Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 551. India Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 552. India Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 553. India Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 554. South Korea Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 555. South Korea Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 556. South Korea Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 557. South Korea Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 558. South Korea Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 559. Taiwan Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 560. Taiwan Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 561. Taiwan Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 562. Taiwan Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 563. Taiwan Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 564. Australia Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 565. Australia Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 566. Australia Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 567. Australia Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 568. Australia Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 569. Rest of Asia-Pacific Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 570. Rest of Asia-Pacific Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 571. Rest of Asia-Pacific Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 572. Rest of Asia-Pacific Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 573. Rest of Asia-Pacific Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 574. Europe Multiplex Assays Sales, by Country K Units (2025-2030)
  • Table 575. Europe Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 576. Europe Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 577. Europe Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 578. Europe Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 579. Europe Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 580. Germany Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 581. Germany Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 582. Germany Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 583. Germany Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 584. Germany Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 585. France Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 586. France Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 587. France Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 588. France Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 589. France Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 590. Italy Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 591. Italy Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 592. Italy Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 593. Italy Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 594. Italy Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 595. United Kingdom Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 596. United Kingdom Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 597. United Kingdom Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 598. United Kingdom Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 599. United Kingdom Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 600. Netherlands Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 601. Netherlands Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 602. Netherlands Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 603. Netherlands Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 604. Netherlands Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 605. Rest of Europe Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 606. Rest of Europe Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 607. Rest of Europe Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 608. Rest of Europe Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 609. Rest of Europe Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 610. MEA Multiplex Assays Sales, by Country K Units (2025-2030)
  • Table 611. MEA Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 612. MEA Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 613. MEA Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 614. MEA Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 615. MEA Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 616. Middle East Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 617. Middle East Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 618. Middle East Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 619. Middle East Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 620. Middle East Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 621. Africa Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 622. Africa Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 623. Africa Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 624. Africa Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 625. Africa Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 626. North America Multiplex Assays Sales, by Country K Units (2025-2030)
  • Table 627. North America Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 628. North America Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 629. North America Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 630. North America Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 631. North America Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 632. United States Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 633. United States Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 634. United States Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 635. United States Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 636. United States Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 637. Canada Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 638. Canada Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 639. Canada Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 640. Canada Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 641. Canada Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 642. Mexico Multiplex Assays Sales, by Type K Units (2025-2030)
  • Table 643. Mexico Multiplex Assays Sales, by Application K Units (2025-2030)
  • Table 644. Mexico Multiplex Assays Sales, by Technology K Units (2025-2030)
  • Table 645. Mexico Multiplex Assays Sales, by Product K Units (2025-2030)
  • Table 646. Mexico Multiplex Assays Sales, by End-Use K Units (2025-2030)
  • Table 647. Multiplex Assays: by Type(USD/Units)
  • Table 648. Research Programs/Design for This Report
  • Table 649. Key Data Information from Secondary Sources
  • Table 650. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Multiplex Assays: by Type USD Million (2018-2023)
  • Figure 5. Global Multiplex Assays: by Application USD Million (2018-2023)
  • Figure 6. Global Multiplex Assays: by Technology USD Million (2018-2023)
  • Figure 7. Global Multiplex Assays: by Product USD Million (2018-2023)
  • Figure 8. Global Multiplex Assays: by End-Use USD Million (2018-2023)
  • Figure 9. South America Multiplex Assays Share (%), by Country
  • Figure 10. Asia Pacific Multiplex Assays Share (%), by Country
  • Figure 11. Europe Multiplex Assays Share (%), by Country
  • Figure 12. MEA Multiplex Assays Share (%), by Country
  • Figure 13. North America Multiplex Assays Share (%), by Country
  • Figure 14. Global Multiplex Assays: by Type K Units (2018-2023)
  • Figure 15. Global Multiplex Assays: by Application K Units (2018-2023)
  • Figure 16. Global Multiplex Assays: by Technology K Units (2018-2023)
  • Figure 17. Global Multiplex Assays: by Product K Units (2018-2023)
  • Figure 18. Global Multiplex Assays: by End-Use K Units (2018-2023)
  • Figure 19. South America Multiplex Assays Share (%), by Country
  • Figure 20. Asia Pacific Multiplex Assays Share (%), by Country
  • Figure 21. Europe Multiplex Assays Share (%), by Country
  • Figure 22. MEA Multiplex Assays Share (%), by Country
  • Figure 23. North America Multiplex Assays Share (%), by Country
  • Figure 24. Global Multiplex Assays: by Type USD/Units (2018-2023)
  • Figure 25. Global Multiplex Assays share by Players 2023 (%)
  • Figure 26. Global Multiplex Assays share by Players (Top 3) 2023(%)
  • Figure 27. Global Multiplex Assays share by Players (Top 5) 2023(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. Luminex Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 30. Luminex Corporation (United States) Revenue: by Geography 2023
  • Figure 31. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 32. Thermo Fisher Scientific (United States) Revenue: by Geography 2023
  • Figure 33. Illumina (United States) Revenue, Net Income and Gross profit
  • Figure 34. Illumina (United States) Revenue: by Geography 2023
  • Figure 35. Bio-Rad Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 36. Bio-Rad Laboratories (United States) Revenue: by Geography 2023
  • Figure 37. Qiagen (Germany) Revenue, Net Income and Gross profit
  • Figure 38. Qiagen (Germany) Revenue: by Geography 2023
  • Figure 39. Abcam (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 40. Abcam (United Kingdom) Revenue: by Geography 2023
  • Figure 41. Becton Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 42. Becton Dickinson and Company (United States) Revenue: by Geography 2023
  • Figure 43. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 44. Merck (United States) Revenue: by Geography 2023
  • Figure 45. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 46. Agilent Technologies (United States) Revenue: by Geography 2023
  • Figure 47. Meso Scale Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 48. Meso Scale Diagnostics (United States) Revenue: by Geography 2023
  • Figure 49. Randox Laboratories (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 50. Randox Laboratories (United Kingdom) Revenue: by Geography 2023
  • Figure 51. Quanterix (United States) Revenue, Net Income and Gross profit
  • Figure 52. Quanterix (United States) Revenue: by Geography 2023
  • Figure 53. Bio-Techne (United States) Revenue, Net Income and Gross profit
  • Figure 54. Bio-Techne (United States) Revenue: by Geography 2023
  • Figure 55. Global Multiplex Assays: by Type USD Million (2025-2030)
  • Figure 56. Global Multiplex Assays: by Application USD Million (2025-2030)
  • Figure 57. Global Multiplex Assays: by Technology USD Million (2025-2030)
  • Figure 58. Global Multiplex Assays: by Product USD Million (2025-2030)
  • Figure 59. Global Multiplex Assays: by End-Use USD Million (2025-2030)
  • Figure 60. South America Multiplex Assays Share (%), by Country
  • Figure 61. Asia Pacific Multiplex Assays Share (%), by Country
  • Figure 62. Europe Multiplex Assays Share (%), by Country
  • Figure 63. MEA Multiplex Assays Share (%), by Country
  • Figure 64. North America Multiplex Assays Share (%), by Country
  • Figure 65. Global Multiplex Assays: by Type K Units (2025-2030)
  • Figure 66. Global Multiplex Assays: by Application K Units (2025-2030)
  • Figure 67. Global Multiplex Assays: by Technology K Units (2025-2030)
  • Figure 68. Global Multiplex Assays: by Product K Units (2025-2030)
  • Figure 69. Global Multiplex Assays: by End-Use K Units (2025-2030)
  • Figure 70. South America Multiplex Assays Share (%), by Country
  • Figure 71. Asia Pacific Multiplex Assays Share (%), by Country
  • Figure 72. Europe Multiplex Assays Share (%), by Country
  • Figure 73. MEA Multiplex Assays Share (%), by Country
  • Figure 74. North America Multiplex Assays Share (%), by Country
  • Figure 75. Global Multiplex Assays: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Luminex Corporation (United States)
  • Thermo Fisher Scientific (United States)
  • Illumina (United States)
  • Bio-Rad Laboratories (United States)
  • Qiagen (Germany)
  • Abcam (United Kingdom)
  • Becton Dickinson and Company (United States)
  • Merck (United States)
  • Agilent Technologies (United States)
  • Meso Scale Diagnostics (United States)
  • Randox Laboratories (United Kingdom)
  • Quanterix (United States)
  • Bio-Techne (United States)
Additional players considered in the study are as follows:
Seegene Inc (South Korea) , Olink (Sweden) , Others
Select User Access Type

Key Highlights of Report


Apr 2024 213 Pages 60 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Multiplex Assays Quantitative research analysis
Global Multiplex Assays Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Luminex Corporation (United States), Thermo Fisher Scientific (United States), Illumina (United States), Bio-Rad Laboratories (United States), Qiagen (Germany), Abcam (United Kingdom), Becton Dickinson and Company (United States), Merck (United States), Agilent Technologies (United States), Meso Scale Diagnostics (United States), Randox Laboratories (United Kingdom), Quanterix (United States) and Bio-Techne (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Incidence of Cancer and Increasing Adoption of Targeted Therapy" is seen as one of major influencing trends for Multiplex Assays Market during projected period 2023-2030.
The Multiplex Assays market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Multiplex Assays Report?

Have a Query? Click Here

Other Related Reports

Angiography Equipment Comprehensive Study by Type (Angiography Systems, Catheters, Guidewire, Balloons, Contrast Media), Application (Diagnostic, Therapeutic, Patient Care Setting), Technology (X-Ray...
$ 3750
Biosafety cabinet Comprehensive Study by Type (Class I, Class II (Type A, Type B), Class III), Application (Teaching Laboratory, Research Institute, Pharmaceutical & Biopharmaceutical Companies, Diag...
$ 3450
Natural and Organic Tampons Comprehensive Study by Type (Radially Wound Pledget Tampons, Square/Rectangular Tampons), Application (<18 Ages, 18-30 Ages, >30 Ages), By Distribution Channels (Online St...
$ 3350
Fitness Technology Comprehensive Study by Type (Wristband, Pocket / Clip, Chest Strap, Pendant), Connectivity (Bluetooth, LTE), Material (Stainless Steel, Nylon, Rubber, Plastic, Silicone), Gender (...
$ 3500
Bimetal Thermometers Comprehensive Study by Type (EI Bimetal Thermometer, CI Bimetal Thermometer, EL Bimetal Thermometer), Distribution Channel (Online, Offline), End User (Oil & Gas Industry, Energy...
$ 3450
Bariatric Devices Comprehensive Study by Type (Minimally Invasive Surgical Devices, Non-invasive Surgical Devices), Application (Bariatric Surgery Clinics, Hospitals, Ambulatory Surgical Centers), Pr...
$ 3450